

European Society for Clinical Virology  
(Limited by guarantee)

Report and Financial Statements  
for the year ended 31 October 2023

**Members of Executive - Company Directors**  
**(November 1<sup>st</sup> 2022 - October 31<sup>st</sup> 2023)**

Prof. Dr. Pamela Vallely (President)  
Prof. Dr. Mariet C.W. Feltkamp (Past President)  
Prof. Dr. Marcus Panning (Vice President)  
Prof. Dr. Maria São José Alexandre Nascimento (Vice President)  
Prof. Dr. Catherine Moore (General Secretary)  
Prof. Dr. Xavier López-Labrador (Communication Officer)  
Prof. Dr. George Sourvinos (Treasurer)  
Prof. Dr. Heli Harvala (Meetings Secretary)

**Company Secretary**

Ester Zoroa, Kenes Group, KAM

**European Society for Clinical Virology (ESCV) details**

Registered Office  
Charles Darwin House  
12 Roger Street  
London

Company limited by guarantee  
N° 04620455

Registered as a Charity in England  
N° 1099537

Inland Revenue reference:  
610 94961 19846 A 01

## **Directors' Report**

The European Society for Clinical Virology (ESCV) is a Company Limited by Guarantee, first incorporated in 2003. In accordance with the Society's Memorandum of Association, each Company Member undertakes to contribute such amount as may be required, not exceeding £1, to the Company's assets if it should be wound up while he or she is a Company Member or within one year after he or she ceases to be so.

The Society is registered as a Charity, the Company Directors being the Charity's Trustees.

The Company Directors acting collectively are the Society's Executive.

The Executive hereby submits its report and financial statements for the year ending October 31<sup>st</sup> 2023.

## ***Organization and Objectives***

According to the articles, the Society is administered by the Executive, made up of minimum three and maximum ten Company Directors/Charity Trustees. Currently the Executive numbers eight Directors.

The ESCV has appointed a professional secretariat to handle administrative matters. This secretariat is Kenes Group, Rue François-Versonnex 7, 1207 Geneva, Switzerland.

In accordance with Article 4 the Executive admits as 'ESCV Members' such persons and subjects them to such rights and obligations as it thinks fit. Such 'ESCV Members' are not Company Members for the purposes of the Articles and are not entitled to vote on any matter save where expressly provided in the Articles.

ESCV members of different European and other countries are represented by councilors, elected by each country's members according to procedures described in the Articles. The councilors acting collectively are the Council. The Council elects the Company Directors/Charity Trustees according to procedures described in the Articles.

The Society's objectives are to promote public health and to advance public education, in particular medical education, by:

- improving the knowledge of viruses, particularly as it relates to the diagnosis and management of viral diseases, their pathogenesis, natural history and prevention.
- improving diagnostic methods.
- promoting high standards in laboratory viral diagnosis through quality assessment activities and education; and
- promoting or developing for the benefit of the public the preparation and exchange of reference reagents.

## ***Reserves Policy***

The Executive has the policy to maintain sufficient funds to allow the Society to meet its objectives and obligations on a long-term basis, and to provide a measure of investment income. It is the objective of the Society to utilize fully each year's net income for its charitable activities.

## ***Review of Activities in 2022/2023***

### **Scientific Meetings**

- Europic Meeting (virtual), June 2022.
- ECCI Meeting, Athens, October 2022.
- 24<sup>th</sup> Annual Conference of the ESCV, 7-10 September 2022. Manchester (UK).
- NGS workshop, 17-18 November 2022. Antalya (Turkey).
- NGS workshop, 23<sup>rd</sup> and 24<sup>th</sup> January 2023. London (UK).
- ESCV – ECCI workshop on Congenital CMV Infection, 26<sup>th</sup> and 27<sup>th</sup> April 2023. Crete (Greece).
- 25<sup>th</sup> Annual Conference of the ESCV, 30<sup>th</sup> August – 2<sup>nd</sup> of September 2023 Milan (Italy).

### **Awards given at the 25<sup>th</sup> Annual Conference of the European Society for Clinical Virology 2023 (Milan)**

- Abbott Award 2023 to Dr. Marianne Graninger.
- BioMerieux Award 2023 to Prof. Marcus Panning.
- Gardner Lectureship Award 2023 to Dr. Charles Chiu.
- Heine-Medin Award 2023 to Dr. Maria F Perdomo.

### **Travel grants and fellowships given**

- 35 virologists received a grant to attend the 25<sup>th</sup> Annual Conference of the European Society for Clinical Virology

### **Training grants**

- None

### **Business Meetings held**

- ESCV Executive Meetings were held on 2<sup>nd</sup> of February, 23<sup>rd</sup> of March, 4<sup>th</sup> of May, 25<sup>th</sup> of May, 22<sup>nd</sup> of June, 13<sup>th</sup> of July, 30<sup>th</sup> of August, 28<sup>th</sup> of September, 26<sup>th</sup> October and 23<sup>rd</sup> of November 2023.
- Council Meeting was held on 30<sup>th</sup> of August 2023.
- General Assembly was held on 1<sup>st</sup> of September 2023.

### **Future Scientific Meetings planned**

- 26<sup>th</sup> Annual Conference of the ESCV, 17<sup>th</sup> – 21<sup>st</sup> September 2024 (Frankfurt, Germany).

-----

Signed on behalf of the Executive (Company Directors),

A handwritten signature in black ink, appearing to read 'P Vallely', is centered within a light gray rectangular box.

Prof. Dr. Pam Vallely  
Company President

## Statement of financial activities (incorporating the income and expenditure account)

Year ended 31 October 2023

### Balance sheet accounts as at October 31, 2023

	Notes	2023 EUR	2023 GBP 0.87237	2022 EUR	2022 GBP 0.85790
<b><u>ASSETS</u></b>					
Bank account	3	197'958	172'692	318'476	273'220
		<b>197'958</b>	<b>172'692</b>	<b>318'476</b>	<b>273'220</b>
<b><u>LIABILITIES</u></b>					
Accounts payable		23'922	20'869	-	-
		<b>23'922</b>	<b>20'869</b>	-	-
<b><u>GENERAL RESERVES</u></b>					
General reserves brought forward		318'476	273'220	261'194	224'078
Result of the year		-144'440	-126'005	57'282	49'142
Foreign exchange conversion		-	4'608	-	-
		<b>174'036</b>	<b>151'823</b>	<b>318'476</b>	<b>273'220</b>
		<b>197'958</b>	<b>172'692</b>	<b>318'476</b>	<b>273'220</b>

**Income & Expenses from 1 November 2022 to 31 October 2023**

	Notes	2023 EUR	2023 GBP 0.87237	2022 EUR	2022 GBP 0.85790
<b><u>INCOMES</u></b>					
Membership fees		30'583	26'679	20'303	17'418
Sponsorship		5'618	4'901	26'000	22'305
Congress income		47'718	41'628	77'612	66'583
		<b>83'919</b>	<b>73'208</b>	<b>123'915</b>	<b>106'306</b>
<b><u>EXPENSES</u></b>					
Travel grants		84'578	73'783	40'242	34'523
Workshop expenses		91'469	79'795	-	-
Congress expenses		23'378	20'394	-	-
Journal expenses		4'690	4'091	2'371	2'034
Administrative expenses		17'640	15'389	22'272	19'107
Bank charges		6'604	5'761	1'748	1'500
		<b>228'359</b>	<b>199'213</b>	<b>66'633</b>	<b>57'164</b>
<b>Net result of the year</b>		<b>-144'440</b>	<b>-126'005</b>	<b>57'282</b>	<b>49'142</b>



### **Audit Exemption**

(a) For the year ended 31 October 2023 the company was entitled to exemption from audit under section 477(2) of the Companies Act 2006 relating to small companies.

(b) Members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476 of the Companies Act 2006.

(c) The directors acknowledge their responsibility for:

- i. ensuring the company keeps accounting records which comply with section 386; and
- ii. preparing accounts which give a true and fair view of the state of affairs of the company as at the end of the financial year, and of its profit or loss for the financial year, in accordance with the requirements of section 393, and which otherwise comply with the requirements of the Companies Act relating to accounts, so far as applicable to the company.

(d) These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

**Approved by Executive on 3<sup>rd</sup> June 2024 and signed on its behalf by Prof. Dr. Pam Vallely (Company President).**



Prof. Pamela Vallely  
**Company President**

This page is left blank intentionally (last page)

**European Society for Clinical Virology**

**(Company limited by guarantee)**

London - United Kingdom

**Financial Statements**

**as at**

**31 October 2023**

**EUROPEAN SOCIETY FOR CLINICAL VIROLOGY, LONDON**  
**Balance sheet accounts as at October 31, 2023**

	Notes	2023 EUR	2023 GBP 0.87237	2022 EUR	2022 GBP 0.85790
<b><u>ASSETS</u></b>					
Bank account	3	197'958	172'692	318'476	273'220
		<b>197'958</b>	<b>172'692</b>	<b>318'476</b>	<b>273'220</b>
<b><u>LIABILITIES</u></b>					
Accounts payable		23'922	20'869	-	-
		<b>23'922</b>	<b>20'869</b>	-	-
<b><u>GENERAL RESERVES</u></b>					
General reserves brought forward		318'476	273'220	261'194	224'078
Result of the year		-144'440	-126'005	57'282	49'142
Foreign exchange conversion		-	4'608	-	-
		<b>174'036</b>	<b>151'823</b>	<b>318'476</b>	<b>273'220</b>
		<b>197'958</b>	<b>172'692</b>	<b>318'476</b>	<b>273'220</b>



Authorized signature

Authorized signature

Date \_\_\_\_\_

**EUROPEAN SOCIETY FOR CLINICAL VIROLOGY, LONDON**  
**Income & Expenses from 1 November 2022 to 31 October 2023**

	Notes	2023 EUR	2023 GBP 0.87237	2022 EUR	2022 GBP 0.85790
<b><u>INCOMES</u></b>					
Membership fees		30'583	26'679	20'303	17'418
Sponsorship		5'618	4'901	26'000	22'305
Congress income		47'718	41'628	77'612	66'583
		<b>83'919</b>	<b>73'208</b>	<b>123'915</b>	<b>106'306</b>
<b><u>EXPENSES</u></b>					
Travel grants		84'578	73'783	40'242	34'523
Workshop expenses		91'469	79'795	-	-
Congress expenses		23'378	20'394	-	-
Journal expenses		4'690	4'091	2'371	2'034
Administrative expenses		17'640	15'389	22'272	19'107
Bank charges		6'604	5'761	1'748	1'500
		<b>228'359</b>	<b>199'213</b>	<b>66'633</b>	<b>57'164</b>
<b>Net result of the year</b>		<b>-144'440</b>	<b>-126'005</b>	<b>57'282</b>	<b>49'142</b>

**EUROPEAN SOCIETY FOR CLINICAL VIROLOGY, LONDON**  
**Notes to the Accounts of October 31, 2023**

**1- GENERAL**

EUROPEAN SOCIETY FOR CLINICAL VIROLOGY "ESCV", is registered as Charity under reference number 1099537.

The Private Limited Company by guarantee reference number is 04620455.

ESCV was incorporated on December 18, 2002.

The mission of ESCV is to provide a forum for virologists, scientists and physicians interested in all aspects of Clinical Virology and human viral diseases.

The registered office is at Charles Darwin House, 12 Roger Street, London WC1N 2JU, United Kingdom.

ESCV officers are :

- Pamela Josephine Vallely
- Catherine Moore
- Xavier Lopez Labrador
- Georgios Sourvinos
- Mariet Feltkamp
- Heli Harvala
- Maria Sao Jose Garcia Alexandre Naschimento
- Marcus Panning

**2 - AUDIT EXEMPTION**

For the year ended 31 October 2023, the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibility for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

**3 – EMPLOYEES**

No employees for this year.

**4 – BANK ACCOUNT**

Represent unrestricted cash balance in Euro held at BBVA Bank in Spain.



# CHARITY COMMISSION FOR ENGLAND AND WALES

## Independent examiner's report on the accounts

### Section A

### Independent Examiner's Report

**Report to the trustees/  
members of**

Charity Name

European Society for Clinical Virology

**On accounts for the year  
ended**

31<sup>st</sup> October 2023

**Charity no  
(if any)**

1099537

**Set out on pages**

2 pages

(remember to include the page numbers of additional sheets)

I report to the trustees on my examination of the accounts of the above charity ("the Trust") for the year ended 31/10/2023.

**Responsibilities and  
basis of report**

As the charity trustees of the Trust, you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ("the Act").

I report in respect of my examination of the Trust's accounts carried out under section 145 of the 2011 Act and in carrying out my examination, I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

**Independent  
examiner's statement**

I have completed my examination. I confirm that no material matters have come to my attention (other than that disclosed below \*) in connection with the examination which gives me cause to believe that in, any material respect:

- accounting records were not kept in accordance with section 130 of the Act or
- the accounts do not accord with the accounting records

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in order to enable a proper understanding of the accounts to be reached.

*\* Please delete the words in the brackets if they do not apply.*

**Signed:**

**Date:**

July 1<sup>st</sup> 2024

**Name:**

Annelies Riezebos-Brilman

**Relevant professional  
qualification(s) or body  
(if any):**

Consultant medical microbiology

**Address:**

Laboratory for Medical Microbiology and Public Health

P.O. box 516  
7550 AM Hengelo (ov.)

The Netherlands

Only complete if the examiner needs to highlight matters of concern (see CC32, Independent examination of charity accounts: directions and guidance for examiners).

**Give here brief details of any items that the examiner wishes to disclose.**